Sanofi SA (SASY.PA)
|Market Cap (Mil.):||€116,091.30|
|Shares Outstanding (Mil.):||1,325.21|
PARIS - An experimental drug from Sanofi and Regeneron significantly reduced congestion in in a mid-stage trial on patients with chronic sinusitis with nasal polyps, a condition poorly controlled by existing drugs, the companies said on Tuesday.
* Dupilumab significantly reduced nasal polyps and congestion
NEW YORK, Sept 25 - MannKind Corp shares were among the most actively traded in premarket on Thursday, after the company said it had closed a licensing agreement with Sanofi for the development and commercialization of its inhaled insulin product.
* Signs extension to shared research agreement with Sanofi until May 2015
PARIS - French drugmaker Sanofi announced on Wednesday a partnership with U.S.-based MyoKardia to develop therapies for patients with genetic heart diseases.
PARIS, Sept 17 - French drugmaker Sanofi announced on Wednesday a partnership with U.S.-based MyoKardia to develop therapies for patients with genetic heart diseases.
PARIS - (This story corrects the Sept.11 story. In the 10th paragraph, the quote should be attributed to Bill Sibold, not Mike Panzara)
(Corrects Sept.11 story. In 10th paragraph, quote should be attributed to Bill Sibold, not Mike Panzara)
PARIS - Sanofi rare disease unit Genzyme hopes to become a leader in the multiple sclerosis (MS) field with the help of new products developed in-house but also through acquisitions, senior Genzyme executives told Reuters.
PARIS - Sanofi rare disease unit Genzyme said its Lemtrada multiple sclerosis (MS) drug showed continued efficacy for four years in more than two thirds of patients and that no new safety risks had been identified in its latest studies.
Earnings vs. Estimates
Analyst Research Reports
Trading Report for (SNY). A detailed report, including free correlated market analysis, and updates.
Provider: Stock Traders Daily
"The Economy Matters" Report for SNY: the economy's impact on SNY's price and risk, featuring the powerful Economic Climate Rating and the new MacroRisk "Stoplight" and Risk Correspondence Score
Provider: MacroRisk Analytics/EconomicInvestor
Provider: ValuEngine, Inc.
Sanofi-Aventis - Finlabo Research Equity Report: Fundamental and Technical Analysis and 6 months performance forecast
Provider: Finlabo SIM Spa
Provider: S&P Capital IQ – STARS Reports
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.